PATENT CLAIM ANALYSIS

Application Number: 15890431
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["424", "134100"]

Abstract:
The invention relates to methods for the temporal administration of EDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal appendages. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED.

Claim (Index 4):
The mehtof of  claim 3 , wherein said treatment of the mother is parenterally by a method selected from the group consisting of in utero injection, intravenous injection, or intra-arterial injection.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 88.0
- Lexical Diversity: 1.39216
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14861292', '14117431', '15030502', '13260937', '13791055']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8114524458737794
- 35 USC 102 Novelty (BERT): 0.6062105455588422
- Combined Prediction Score: 0.7909282558422857
- Mean Citation Score: 495.17748200000005
- Max Citation Score: 676.22015
- Similarity Product: 438.3645782835871

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test